Federation Des Caisses Desjardins Du Quebec Xeris Biopharma Holdings, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.04 - $3.22 $1,162 - $1,835	570 New	570 $1.26 Million
Q4 2023 Aug 14, 2024	BUY	$1.47 - $2.36 $837 - $1,345	570 New	570 $1.34 Million
Q2 2022 Aug 14, 2024	SELL	$1.48 - $2.64 $444 - $792	-300 Closed	0 $0
Q1 2022 Aug 14, 2024	BUY	$2.0 - $2.87 $600 - $861	300 New	300 $768,000

Others Institutions Holding XERS

# of Institutions

142

Shares Held

59.9M

Call Options Held

148K

Put Options Held

45.7K

Black Rock Inc. New York, NY

10.3M
Shares

$34.8 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

7.77M
Shares

$26.2 Million
0.0% of portfolio
Caxton Corp Princeton, NJ

5.11M
Shares

$17.2 Million
62.59% of portfolio
Center Book Partners LP Greenwich, CT

3.48M
Shares

$11.7 Million
0.64% of portfolio
Geode Capital Management, LLC Boston, MA

3.33M
Shares

$11.2 Million
0.0% of portfolio

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $458M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account